Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by WalterTheDawgon Jul 14, 2022 9:20am
117 Views
Post# 34823597

RE:Walter

RE:Walter Thanks for the heads up Rambo! And Budaman, I think your expectations may be a bit high but I appreciate your enthusiasm for the stock and positivity. I could use some of that but instead I tend to view things in a very conservative manner. There are a number of red flags I'm seeing right now that are reminiscent of how things went in 2020. I just don't understand the radio silence on the phase 2 trial analysis and suspect they may have unforeseen issues, a short update on the process and what is being done would stabilize the SP and could have helped fill the PP, but they obviously don't feel confident enough to even mention it in an NR or video. I hope my suspicions are incorrect. The company likely needs more time to analyze the data and they may not want to lean too heavily on results until they know everything checks out. . Good luck to us all.
<< Previous
Bullboard Posts
Next >>